SCHEMBL770717

SCHEMBL770717

COc1ccccc1N1CCN(C(=O)C(=O)N2CCC3CCCC=C3C2)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.52
TACR3 P29371 1/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
POLB P06746 2/20 0.49
RAB9A P51151 1/20 0.48
KDM4E B2RXH2 2/20 0.48
AKR1C3 P42330 1/20 0.48
TSHR P16473 4/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH1A1 P00352 3/20 0.47
EED O75530 1/20 0.47
HPGDS O60760 1/20 0.47
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769569 0.89 RAB9A (0.53) TACR3KMT2AMEN1POLBRAB9A
SCHEMBL771534 0.89 L3MBTL1 (0.57) KMT2AMEN1POLBRAB9AKDM4E
SCHEMBL769689 0.87 L3MBTL1 (0.53) KMT2AMEN1POLBRAB9AKDM4E
SCHEMBL772030 0.86 TSHR (0.52) KMT2AMEN1AKR1C3TSHRNPSR1
SCHEMBL770999 0.82 PKM (0.51) PKMTACR3KMT2AMEN1POLB
SCHEMBL16026545 0.80 PKM (0.74) PKMKMT2AMEN1POLBRAB9A
SCHEMBL772492 0.79 L3MBTL3 (0.33) POLBRAB9ASMN1; SMN2ALDH1A1
SCHEMBL771570 0.78 L3MBTL3 (0.37) KMT2APOLBLMNASMN1; SMN2ALDH1A1
SCHEMBL770485 0.76 ACHE (0.38) KMT2AMEN1POLBRAB9ATSHR
SCHEMBL770716 0.76 PKM (0.56) PKMTACR3KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 PKM 1551/4885TACR3 4428/4885KMT2A 3868/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 PKM 1554/4885TACR3 4442/4885KMT2A 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.